Using omega-3 fatty acids to improve treatment for liver cancer.
Docosahexaenoic Acid Loaded Low-density Lipoproteins: A Novel Biologic Intervention for Hepatocellular Carcinoma.
This study is looking at a new way to help people with liver cancer by using a special form of omega-3 fatty acid to make the current treatment work better, with the hope of improving how well the treatment helps and how long patients live.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11001138 on NIH RePORTER |
What this research studies
This research investigates the use of docosahexaenoic acid (DHA), a natural omega-3 fatty acid, loaded into low-density lipoproteins as a new treatment approach for hepatocellular carcinoma (HCC). The study aims to enhance the effectiveness of transarterial chemoembolization (TACE), the current first-line treatment for intermediate-stage HCC, which often has limited success. By targeting the underlying mechanisms that contribute to tumor growth and liver function deterioration, this innovative therapy seeks to improve patient outcomes and survival rates. Patients may be monitored for changes in tumor response and liver health as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with intermediate-stage hepatocellular carcinoma who are undergoing or are candidates for transarterial chemoembolization.
Not a fit: Patients with early-stage or advanced hepatocellular carcinoma who are not eligible for TACE may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with hepatocellular carcinoma, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promising results using omega-3 fatty acids in cancer treatment, suggesting that this approach may have potential benefits.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Corbin, Ian Ronald — Ut Southwestern Medical Center
- Study coordinator: Corbin, Ian Ronald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.